- Global Pharma News & Resources
PharmiWeb Today Story
Transformational multi-billion dollar collaboration with Gilead to create a global R&D leader based in Europe

Today, Galapagos announces transformational multi-billion dollar collaboration with Gilead to create a global R&D leader based in Europe, developing and commercialising breakthrough therapies to patients. Please see the press releases

  • Multi-billion dollar collaboration is one of the largest ever biotech deals in Europe - $3.95 billion upfront payment, a $1.1bn equity investment by GILD, $1.1bn additional opt-in payments for two late stage products, as well as additional milestones to access early pipeline assets, and double digit royalties.
  • Creates a global R&D leader - Collaboration will accelerate GLPG’s vision to become a top 10 global biotech company and establish global leadership in inflammation & immunology. GLPG’s enhanced financial strength will enable it to increase investment into R&D to expedite development timelines for new and existing pipeline programmes. Under the collaboration, GLGP gains broader commercialisation rights in Europe for Filgotinib; it plans to establish a European commercial infrastructure to commercialise Filgotinib and retains European rights to current and future pipeline products.
  • GLPG retains its independence which nurtures its R&D culture and maintains the entrepreneurial spirit that has driven its successes to date, whilst strengthening its relationship with GILD, a committed partner with proven development and commercial capabilities globally, resulting in multiple blockbusters.
  • Galapagos expands EU co-commercialization rights for filgotinib and plans to accelerate the build up …